Dry skin, itching, and fiery eczema can be caused by allergens, stress, or an overactive immune response.Steroid creams ...

Some patients with psoriasis may have a super response to guselkumab, but questions remain regarding the generalizability of treatment strategies.

In a cohort of more than 11,000 patients from the U.K. and Ireland, a comparable proportion of new adalimumab users achieved ...

Opens in a new tab or window Until about 20 years ago, systemic treatment options for moderate/severe psoriasis were limited and nonspecific. To get an idea of how much the field has changed ...

Mar. 3, 2025 — Psoriasis is one of the most common chronic inflammatory skin diseases, affecting around 250,000 people in Austria. While previous treatment approaches have mainly focused on ...

Tildrakizumab showed early and sustained effectiveness and quality of life (QOL) improvements in patients with moderate to ...

Psoriasis is one of the most common chronic inflammatory skin diseases, affecting around 250,000 people in Austria.

Initiating methotrexate within 2 years of a psoriasis diagnosis is associated with a reduced risk of progressing to PsA.

Five-year data from Phase III trials demonstrated that 67.7% of patients moderate-to-severe plaque psoriasis treated with UCB ...

Researchers have discovered a strong association between the use of immune checkpoint inhibitors for cancer treatment and a ...

Patients treated with ESK-001 for moderate to severe plaque psoriasis experienced positive clinical responses through a year, ...

Bristol Myers Squibb has released new 5-year results from the long-term trial evaluating Sotyktu for the treatment of adults ...